Blocking IKK-mediated IĸBα degradation and NF-ĸB activation, repression of NF-ĸB transactivation potential and stabilization of IĸB has been shown to inhibit aberrant gene expression, malignant phenotypes and therapeutic resistance in pre-clinical models of prostate cancer [11–14]. Here, ATP8A2 is linked to Familial prostate cancer.